← Back to Search

Stem Cell Therapy

human retinal progenitor cells for Retinitis Pigmentosa

Phase 2
Waitlist Available
Led By Mitul Mehta, MD
Research Sponsored by jCyte, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This study is evaluating whether a new treatment for retinitis pigmentosa is safe.

Eligible Conditions
  • Retinitis Pigmentosa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of Intravitreal Injection of hRPC
Secondary outcome measures
Best Corrected Visual Acuity
Contrast Sensitivity
Mobility
+1 more

Side effects data

From 2020 Phase 2 trial • 84 Patients • NCT03073733
17%
Conjunctival hemorrhage
10%
Visual acuity reduced
7%
Influenza
7%
Localised infection
3%
Cystoid macular edema
3%
Sinusitis
3%
Intraocular pressure increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sham Treated Control
Test (jCell Injection) Dose Level 1
Test (jCell Injection) Dose Level 2

Trial Design

1Treatment groups
Experimental Treatment
Group I: Retreated subjectsExperimental Treatment1 Intervention
Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
human retinal progenitor cells
2015
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

California Institute for Regenerative Medicine (CIRM)OTHER
63 Previous Clinical Trials
3,118 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
128 Patients Enrolled for Retinitis Pigmentosa
jCyte, IncLead Sponsor
2 Previous Clinical Trials
112 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
112 Patients Enrolled for Retinitis Pigmentosa
Mitul Mehta, MDPrincipal InvestigatorUniversity of California, Irvine/Gavin Herbert Eye Institute
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
2020. "Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04604899.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top